ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Alogliptin repositioning confers protection against diclofenac-induced liver injury by inhibiting TLR4/NF-κB, ROS/TXNIP, and NLRP3 inflammasome-mediated pyroptosis in rats.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced liver injury (DILI) is a significant contributor to post-marketing concerns and drug withdrawals. Diclofenac (Diclo), a nonsteroidal anti-inflammatory drug, has the potential to cause liver injury. Given the current limitations, there is a great demand for finding effective and safe preventive therapies for liver injury. Alogliptin (Alo), a dipeptidyl peptidase-4 (DPP-4) inhibitor, has multifaceted properties; however, its protective effect against Diclo-triggered liver damage remains unveiled. This study aimed to explore the hepatoprotective effect of Alo versus Diclo-evoked liver insult and decipher the underlying molecular mechanisms. Experimental rats were arbitrarily allocated into four groups: Control, Diclo, Alo 20, and Alo 40. Liver injury was evaluated microscopically, and molecular perturbations were estimated by measuring inflammatory, inflammasome, apoptotic, and oxidative stress markers. Our results showed that Alo evidently abrogated Diclo-instigated liver injury, as verified by reduced levels of ALT, AST, and LDH, along with the restoration of liver histoarchitecture. Furthermore, Alo pretreatment remarkably inhibited the perturbations in redox balance induced by Diclo, together with a reduction in inflammatory mediators and apoptotic markers. Mechanistically, Alo pretreatment effectively abated the inflammasome moieties and gasdermin D-N terminal via averting TLR4/TRAF6/NF-κB and ROS/TXNIP signaling pathways, while boosting Nrf2, ultimately curbing Diclo-induced pyroptotic cell death. This study validated the interplay among the TLR4/TRAF6/NF-κB/NLRP3/ASC/cleaved caspase-1, Nrf2/TXNIP, and ROS/TXNIP signaling trajectories in mediating Diclo-induced pyroptosis. Furthermore, it revealed that a dose-dependent hepatoprotective effect of Alo signifies its antioxidant, anti-inflammatory, anti-apoptotic, and anti-pyroptotic actions that could offer a promising strategy for alleviating Diclo-induced hepatotoxicity.
Indexed as
Identifiers
41324663What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.